Pacific Biosciences of California, Inc. (PACB)
Nasdaq · Laboratory Analytical Instruments · Manufacturing · CIK 1299130 · fiscal year ends in Dec
Closing price $2.91 on 29 Oct 2026; 52-week range $1.11 to $2.91.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $159.3M
- Revenue growth
- 2.0%
- Net income, last twelve months
- -$131.4M
- Earnings per share
- -$0.43
- Gross margin
- 36.4%
- Operating margin
- -83.5%
- Net margin
- -82.5%
- Market value
- $904.5M
- Dividend yield
- 0.0%
- Cash
- $61.0M
- Debt
- $644.3M
- Shares outstanding
- 310.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $160.0M | -$553.9M | -$546.4M | -$1.82 | -$113.9M | 10-K filed 25 Feb 2026 |
| FY2024 | 31 Dec 2024 | $154.0M | -$474.3M | -$309.9M | -$1.59 | -$212.2M | 10-K filed 17 Mar 2025 |
| FY2023 | 31 Dec 2023 | $200.5M | -$334.5M | -$306.7M | -$1.21 | -$268.0M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $128.3M | -$307.2M | -$314.2M | -$1.40 | -$280.0M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $130.5M | -$210.4M | -$181.2M | -$0.89 | -$117.1M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $39.0M | -$44.7M | -$0.14 |
| Q1 FY2026 | 31 Mar 2026 | $37.2M | -$8.3M | -$0.03 |
| Q4 FY2025 | 31 Dec 2025 | $44.6M | -$40.4M | -$0.13 |
| Q3 FY2025 | 30 Sep 2025 | $38.4M | -$38.0M | -$0.13 |
| Q2 FY2025 | 30 Jun 2025 | $39.8M | -$41.9M | -$0.14 |
| Q1 FY2025 | 31 Mar 2025 | $37.2M | -$426.1M | -$1.44 |
| Q4 FY2024 | 31 Dec 2024 | $39.2M | $2.4M | -$0.49 |
| Q3 FY2024 | 30 Sep 2024 | $40.0M | -$60.7M | -$0.22 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Consumables revenue | $81.9M | 51.2% |
| Instrument revenue | $53.8M | 33.6% |
| Service and other revenue | $24.2M | 15.2% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Americas | $72.8M | 45.5% |
| Europe, Middle East, and Africa | $44.1M | 27.5% |
| Asia-Pacific | $43.2M | 27.0% |
Company events
The newest 8-K filings of 200 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results, Leadership change, Restructuring, Investor update | 2.02, 2.05, 5.02, 7.01, 9.01 |
| 9 Jul 2026 | 8-K | Leadership change | 5.02 |
| 4 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Mar 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01 |
| 5 Mar 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Feb 2026 | 8-K | Leadership change | 5.02 |
| 2 Feb 2026 | 8-K | Deal completed, Material agreement, Investor update | 1.01, 2.01, 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 426 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | S-8 | – |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 30 Jul 2026 |
| 9 Jul 2026 | 8-K | 8 Jul 2026 |
| 4 Jun 2026 | 8-K | 3 Jun 2026 |
| 27 May 2026 | SD | – |
| 22 May 2026 | DEFA14A | – |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 23 Apr 2026 | ARS | 31 Dec 2025 |
| 23 Apr 2026 | DEFA14A | – |
| 23 Apr 2026 | DEF 14A | 3 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 6 Oct 2026 | Gibson James R Ii, See Remarks | Sale under a trading plan | 661,815 | $3.11 | $2.1M | 1,083,848 | 8 Oct 2026 |
| 17 Aug 2026 | Van Oene Mark, See Remarks | Sale outside a trading plan | 26,911 | $1.13 | $30.4K | 2,705,853 | 18 Aug 2026 |
| 1 Apr 2026 | Gibson James R Ii, See Remarks | Sale outside a trading plan | 88,185 | $1.37 | $120.8K | 1,245,663 | 3 Apr 2026 |
| 3 Mar 2026 | Henry Christian O, See Remarks | Sale outside a trading plan | 12,497 | $1.51 | $18.9K | 3,581,813 | 4 Mar 2026 |
| 3 Mar 2026 | Van Oene Mark, See Remarks | Sale outside a trading plan | 6,504 | $1.51 | $9.8K | 2,243,634 | 4 Mar 2026 |
| 3 Mar 2026 | Farmer Michele, See Remarks | Sale outside a trading plan | 2,979 | $1.51 | $4.5K | 305,948 | 4 Mar 2026 |
| 18 Feb 2026 | Van Oene Mark, See Remarks | Sale outside a trading plan | 55,107 | $1.63 | $89.8K | 1,742,638 | 19 Feb 2026 |
| 18 Feb 2026 | Henry Christian O, See Remarks | Sale outside a trading plan | 140,874 | $1.63 | $229.5K | 2,673,500 | 19 Feb 2026 |
| 18 Feb 2026 | Farmer Michele, See Remarks | Sale outside a trading plan | 14,952 | $1.63 | $24.4K | 219,092 | 19 Feb 2026 |
| 17 Feb 2026 | Van Oene Mark, See Remarks | Sale outside a trading plan | 129,790 | $1.58 | $204.5K | 1,797,745 | 19 Feb 2026 |
| 17 Feb 2026 | Henry Christian O, See Remarks | Sale outside a trading plan | 331,793 | $1.58 | $522.9K | 2,814,374 | 19 Feb 2026 |
| 17 Feb 2026 | Farmer Michele, See Remarks | Sale outside a trading plan | 35,215 | $1.58 | $55.5K | 234,044 | 19 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 6 Oct 2026 | Jim Gibson, Officer | 661,815 | $1.9M | 6 Oct 2026 |
| 17 Aug 2026 | MARK VAN OENE, Officer | 26,911 | $30.5K | 17 Aug 2026 |
| 1 Apr 2026 | JAMES GIBSON, Officer | 88,185 | $120.8K | 1 Apr 2026 |
| 3 Mar 2026 | MARK D. VAN OENE, Officer | 6,504 | $9.8K | 3 Mar 2026 |
| 3 Mar 2026 | CHRISTIAN HENRY, Officer | 12,497 | $18.9K | 3 Mar 2026 |
| 17 Feb 2026 | MARK VAN OENE, Officer | 303,739 | $478.7K | 17 Feb 2026 |
| 17 Feb 2026 | CHRISTIAN HENRY, Officer | 606,312 | $955.5K | 17 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | ARK Investment Management LLC | 13G amended | 9.59% | 29.8M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 3 Feb 2026 | ARK Investment Management LLC | 13G amended | 12.34% | 37.3M |
| 14 Nov 2025 | Madrone Capital Partners, LLC | 13G amended | 2.8% | 8.5M |
| 4 Nov 2025 | ARK Investment Management LLC | 13G amended | 10.3% | 30.9M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 46.9M | -0.62% | 2.19 |
| 30 Sep 2026 | 47.2M | -3.41% | 2.97 |
| 15 Sep 2026 | 48.9M | -1.38% | 10.49 |
| 31 Aug 2026 | 49.6M | -7.18% | 6.75 |
| 14 Aug 2026 | 53.4M | +8.99% | 6.63 |
| 31 Jul 2026 | 49.0M | +5.98% | 7.35 |
| 15 Jul 2026 | 46.2M | -2.64% | 9.97 |
| 30 Jun 2026 | 47.5M | -21.58% | 6.51 |
Funds that hold it
From each fund's latest Form 13F.
252 funds held it at 30 Jun 2026: 92 added and 76 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 32,339,550 | $54.3M | +7,072,121 |
| ARK Investment Management LLC | 29,781,416 | $50.0M | -6,491,872 |
| Softbank Group Corp. | 20,451,570 | $34.4M | 0 |
| Vanguard Capital Management LLC | 13,397,934 | $22.5M | +620,485 |
| Geode Capital Management, LLC | 7,606,518 | $12.8M | +631,252 |
| Sumitomo Mitsui Trust Group, Inc. | 6,009,715 | $10.1M | -1,028,272 |
| Amova Asset Management Americas, Inc. | 6,009,715 | $10.0M | -1,028,272 |
| State Street Corp. | 5,961,175 | $10.0M | -160,541 |
| Point72 Asset Management, L.P. | 4,787,300 | $8.0M | +4,501,600 |
| Two Sigma Investments, LP | 4,242,599 | $7.1M | +732,986 |
Peers
Companies in the same industry.
- Agilent Technologies, Inc. (A): revenue $7.4B, market value $51.1B
- Waters Corp. (WAT): revenue $4.6B, market value $47.1B
- Illumina, Inc. (ILMN): revenue $4.5B, market value $43.7B
- Mettler Toledo International Inc. (MTD): revenue $4.1B, market value $37.3B
- Revvity, Inc. (RVTY): revenue $2.9B, market value $18.5B
- Avantor, Inc. (AVTR): revenue $6.6B, market value $11.3B
- 10x Genomics, Inc. (TXG): revenue $616.9M, market value $10.4B
- Bio-Rad Laboratories, Inc. (BIO): revenue $2.6B, market value $10.3B
- Bruker Corp. (BRKR): revenue $3.5B, market value $9.4B
- Cytek Biosciences, Inc. (CTKB): revenue $206.7M, market value $818.2M